Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.

In a letter sent to hospitals and clinics on Friday, Sanofi indicated that certain hospitals covered by the 340B Drug ...

Sanofi is the third company - along with J&J and Eli Lilly - to attempt to change the way it pays for medicines under the ...

Sanofi is proposing a new model for distributing drug discounts under the federal 340B program, according to the Wall Street ...

Sanofi (SNY) is planning changes to its 340B plan on how it gives discounts to certain hospitals, planning to require institutions to provide ...

Sanofi plans to send a letter, reviewed by WSJ, to hospitals outlining its new model on Friday, the report said, citing ...

French pharma company Sanofi has joined Ely Lilly and Johnson & Johnson in a challenge to the U.S.'s 340B drug discount ...

The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly blockbuster GLP-1 drugs Zepbound and Mounjaro are in shortage. Shares of the ...